Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions

Veracyte

29/09/2026 13:14

** Shares of diagnostics company Veracyte VCYT.O rise 1.6% to $45.94 premarket
** Co says its Decipher test identified intermediate-risk prostate cancer patients most likely to benefit from adding hormone therapy to radiation
** Prostate cancer is a cancer of the prostate gland; hormone therapy lowers hormones that can help tumors grow
** Patients with intermediate/high Decipher scores saw an 8 percentage-point reduction in cancer spread at 10 years when hormone therapy was added, Veracyte says
** About 44% of patients had low scores and saw no significant benefit from added hormone therapy
** Findings are based on a retrospective analysis of 395 patients from a late-stage prostate cancer trial
** As of last close, stock down ~23% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))